KR20260009350A - 멜라노코르틴 2형 수용체 안타고니스트 - Google Patents

멜라노코르틴 2형 수용체 안타고니스트

Info

Publication number
KR20260009350A
KR20260009350A KR1020257041365A KR20257041365A KR20260009350A KR 20260009350 A KR20260009350 A KR 20260009350A KR 1020257041365 A KR1020257041365 A KR 1020257041365A KR 20257041365 A KR20257041365 A KR 20257041365A KR 20260009350 A KR20260009350 A KR 20260009350A
Authority
KR
South Korea
Prior art keywords
group
substituted
compound
mmol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257041365A
Other languages
English (en)
Korean (ko)
Inventor
시게미쓰 마쓰모토
나오요시 노구치
사토시 사사키
미노루 이코마
히데토 후쿠시
료마 하라
고헤이 아사노
고지 와타나베
마사키 오기노
시즈오 가사이
쓰요시 마에카와
히데키 히로세
Original Assignee
가부시키가이샤 스코히아 파마
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 가부시키가이샤 스코히아 파마 filed Critical 가부시키가이샤 스코히아 파마
Publication of KR20260009350A publication Critical patent/KR20260009350A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257041365A 2023-05-16 2024-05-15 멜라노코르틴 2형 수용체 안타고니스트 Pending KR20260009350A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JPJP-P-2023-080580 2023-05-16
JP2023080580 2023-05-16
PCT/JP2024/017921 WO2024237266A1 (ja) 2023-05-16 2024-05-15 メラノコルチン２型受容体アンタゴニスト

Publications (1)

Publication Number Publication Date
KR20260009350A true KR20260009350A (ko) 2026-01-19

Family

ID=93519713

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020257041365A Pending KR20260009350A (ko) 2023-05-16 2024-05-15 멜라노코르틴 2형 수용체 안타고니스트

Country Status (13)

Country Link
EP (1) EP4714953A1 (https=)
JP (1) JPWO2024237266A1 (https=)
KR (1) KR20260009350A (https=)
CN (1) CN120858097A (https=)
AR (1) AR132690A1 (https=)
AU (1) AU2024273541A1 (https=)
CL (1) CL2025003547A1 (https=)
CO (1) CO2025012255A2 (https=)
IL (1) IL324502A (https=)
JO (1) JOP20250278A1 (https=)
MX (1) MX2025013542A (https=)
TW (1) TW202509036A (https=)
WO (1) WO2024237266A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236699A1 (en) 2018-06-05 2019-12-12 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL360855A1 (en) * 2000-06-28 2004-09-20 Pfizer Products Inc. Melanocortin receptor ligands
US12479825B2 (en) * 2019-11-07 2025-11-25 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
JP7734571B2 (ja) 2021-11-30 2025-09-05 株式会社日立製作所 プロセスモデル構築システム、プロセスモデル構築方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019236699A1 (en) 2018-06-05 2019-12-12 Crinetics Pharmaceuticals, Inc. Melanocortin subtype-2 receptor (mc2r) antagonists and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Front Endocrinol(Lausanne). 2016 Aug 5;7:101. doi: 10.3389/fendo.2016.00101. PMID: 27547198; PMCID: PMC4974254.

Also Published As

Publication number Publication date
JPWO2024237266A1 (https=) 2024-11-21
EP4714953A1 (en) 2026-03-25
CO2025012255A2 (es) 2025-09-18
CL2025003547A1 (es) 2026-02-20
AR132690A1 (es) 2025-07-23
IL324502A (en) 2026-01-01
TW202509036A (zh) 2025-03-01
CN120858097A (zh) 2025-10-28
MX2025013542A (es) 2025-12-01
AU2024273541A1 (en) 2025-11-06
JOP20250278A1 (ar) 2025-11-09
WO2024237266A1 (ja) 2024-11-21

Similar Documents

Publication Publication Date Title
TWI877697B (zh) 作為parp7抑制劑的嗒酮
EP3728238B1 (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators
WO2024238633A2 (en) Kras g12s and g12c inhibitors
EP3341367B1 (en) Bicyclic-fused heteroaryl or aryl compounds as irak4 modulators
WO2022266258A1 (en) Compounds and methods for the targeted degradation of irak-4
KR102522832B1 (ko) 호흡기 세포융합 바이러스 （ｒｓｖ）의 복제에 대하여 저해 활성을 갖는 피페리딘 치환된 피라졸로［１，５―ａ］피리미딘 유도체
JP6581111B2 (ja) Ｒｈｏキナーゼ阻害剤としてのイソキノリンスルホン誘導体
JP2022529339A (ja) アンドロゲン受容体を標的に分解する二官能性キメラ複素環式化合物及びその使用
TW202413351A (zh) 藉由irak4抑制劑與e3連接酶配體的軛合降解irak4及使用方法
ES2956090T3 (es) Inhibidores de bencimidazol de enzimas PAD
AU2016371014A1 (en) Polycyclic TLR7/8 antagonists and use thereof in the treatment of immune disorders
CA3007922A1 (en) Therapeutic inhibitory compounds
JP2020515575A (ja) ヘテロ環化合物
BR112019012927A2 (pt) Composto, uso de um composto, combinação de um composto, composição farmacêutica e dispositivo
CA3066946A1 (en) Heteroaromatic compounds as vanin inhibitors
JP2008510006A (ja) 化合物
JP6605121B2 (ja) ヤヌスキナーゼ１選択的阻害剤及びその医薬用途
KR20260009350A (ko) 멜라노코르틴 2형 수용체 안타고니스트
EA030636B1 (ru) Замещенные пиперидином трициклические производные пиразоло[1,5-a]пиримидина с ингибирующей активностью в отношении репликации респираторно-синцитиального вируса (rsv)
AU2021280287A1 (en) TLR2 modulator compounds, pharmaceutical compositions and uses thereof
EP3028703B1 (en) Piperidine derivatives as wnt signaling inhibitor
WO2026055782A1 (en) Compounds and compositions for treating mc4r related conditions
WO2026055780A1 (en) Compounds and compositions for treating mc4r related conditions
EA047011B1 (ru) Производные сульфонилмочевины в качестве модуляторов nlrp3 инфламмасомы
HK40039990A (en) Sulphonyl urea derivatives as nlrp3 inflammasome modulators

Legal Events

Date Code Title Description
D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-EXM-PA0201 (AS PROVIDED BY THE NATIONAL OFFICE)

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)